Search results

Crohn's Disease Forum

Help Support Crohn's Disease Forum:

  1. Crohn2357

    Remicade anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases

    That's not true. When a Crohn's patient is hospitalised (due to active Crohn's, abscesses, fistula etc.), he/she is generally given the antibiotics intravenously, even though the patient can take them orally. IV antibiotics work well for Crohn's in hospitalisations to abort the flare-ups...
  2. Crohn2357

    Remicade anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases

    Thanks for sharing. https://clinicaltrials.gov/ct2/show/NCT01783106 https://www.lctu.org.uk/LCTU_NET/frontend/core/Features/trialinfo.aspx?Data=W1tkSEpwWVd4bmNtOTFjQT09XV1bTUE9PV1bW2RISnBZV3hwWkE9PV1dW01UazRdW1tiRzlqWVd4bF1dW01RPT1d A doctoral thesis submitted to the same university...
  3. Crohn2357

    Remicade anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases

    Qu Biologics With Promising New Treatment for Crohn's Disease - Global TV - May 31, 2013
  4. Crohn2357

    Remicade anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases

    Tyler Wilson - Full Mucosal Healing from Crohn's - Qu Biologics Experimental SSI Medicine Trial Tyler Wilson's Miracle - Full Mucosal Healing of Crohn's - Qu Biologics SSI Medicine Oct 30, 2018 Colleen Miller in 100% Remission from Crohn's since 2012 with QuBiologics Experimental SSI...
  5. Crohn2357

    Remicade anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases

    Maybe @Hal Gunn will write an answer.
  6. Crohn2357

    Remicade anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases

    From Hal Gunn. These clips were uploaded two years ago:
  7. Crohn2357

    Remicade anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases

    I find the results encouraging.
  8. Crohn2357

    Remicade anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases

    Someone shared her conversation with Dr. Hal Gunn on Facebook: https://www.facebook.com/groups/425949470944340/permalink/1079759735563307/
  9. Crohn2357

    Remicade anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases

    "In this work, we present the results from a Phase 1/2 randomized, double-blind, placebo-controlled trial of a novel immunotherapy approach to optimize innate immune function in CD. QBECO, an investigational immunotherapy derived from an inactivated GI pathogen, aims to elicit an acute innate...
  10. Crohn2357

    Remicade anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases

    A comment on that report: Still interesting though.
  11. Crohn2357

    Remicade anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases

  12. Crohn2357

    Remicade anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases

    Some explanatory videos on these topics:
  13. Crohn2357

    Remicade anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases

    Another mechanism for rapamycin, proposed by Greenstein et al.: Antimycobacterial effect. PLoS One. 2008 Jun 25;3(6):e2496. doi: 10.1371/journal.pone.0002496. On the action of cyclosporine A, rapamycin and tacrolimus on M. avium including subspecies paratuberculosis. Greenstein RJ1, Su L, Juste...
  14. Crohn2357

    Remicade anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases

    Discussion While CD is an immune-mediated disease, it is not an autoimmune disease [7, 13]. The CD immunodeficiency hypothesis (IDH), dating in part to the late 1970s [14], asserts that (1) infectious agents breach the bowel mucosal lining, (2) a predisposing innate immune deficiency prompts an...
  15. Crohn2357

    Anti-MAP Therapy Support Group

    William C. Davis, J. Todd Kuenstner & Shoor Vir Singh (2017) Resolution of Crohn’s (Johne’s) disease with antibiotics: what are the next steps?, Expert Review of Gastroenterology &...
  16. Crohn2357

    Remicade anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases

    kiny, could you comment on this article? Here's a summary of it, written by one of its authors: https://humanpara.org/the-long-road-to-the-development-of-a-peptide-based-vaccine-for-mycobacterium-avium-paratuberculosis/ Another summary...
  17. Crohn2357

    "What happens when you have a colonoscopy?"

    I found this short clip interesting. http://www.crohnsmapvaccine.com/what-happens-when-you-have-a-colonoscopy/
  18. Crohn2357

    Anti-MAP Therapy Support Group

    https://humanpara.org/the-long-road-to-the-development-of-a-peptide-based-vaccine-for-mycobacterium-avium-paratuberculosis/ https://vmp.vetmed.wsu.edu/people/faculty/profile/william-c-davis https://www.feedstuffs.com/nutrition-health/map-protein-may-aid-battle-against-johnes-disease
  19. Crohn2357

    Anti-MAP Therapy Support Group

    http://www.crohnsmapvaccine.com/testimonials/
  20. Crohn2357

    Anti-MAP Therapy Support Group

    Human Paratuberculosis Foundation's twitter page: https://twitter.com/HumanPara
View older results
Back
Top